Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Open-Label, Non-Randomized, Multicentre, Dose-Escalation Clinical Trial with Control Group to Evaluate the Safety, Feasibility and Preliminary Efficacy of PRAME TCR Modified T Cells, MDG1011, in Subjects with High Risk Myeloid and Lymphoid Neoplasms

Trial Profile

A Phase I/II, Open-Label, Non-Randomized, Multicentre, Dose-Escalation Clinical Trial with Control Group to Evaluate the Safety, Feasibility and Preliminary Efficacy of PRAME TCR Modified T Cells, MDG1011, in Subjects with High Risk Myeloid and Lymphoid Neoplasms

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Aug 2018

At a glance

  • Drugs MDG 1011 (Primary)
  • Indications Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors MediGene AG
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 09 May 2018 According to a MediGene AG media release, company intends to present preliminary data on certain aspects of the trial at scientific conferences and final data will be available towards the end of 2019.
    • 09 May 2018 According to a MediGene AG media release, company expects to conduct the first trial cohorts of Phase I in the course of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top